Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients : An update
Copyright © 2022. Published by Elsevier Inc.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 239(2022) vom: 03. Juni, Seite 109022 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2022
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Review Research Support, Non-U.S. Gov't Anti-inflammation treatment Coronavirus disease 2019 (COVID-19) Cytokine storm Immune therapy Anti-Inflammatory Agents Hydroxychloroquine 4QWG6N8QKH mehr... |
| Zusammenfassung: | Copyright © 2022. Published by Elsevier Inc. In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and chloroquine/hydroxychloroquine |
|---|---|
| Beschreibung: | Date Completed 02.06.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2022.109022 |